FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019306593> ?p ?o ?g. }

• W2019306593 endingPage "38" @default.
• W2019306593 startingPage "33" @default.
• W2019306593 abstract "The efficacy of murine monoclonal anti-interleukin 2 α chain receptor (Tac) antibodies is limited by a short half-life and the development of antibodies to the heterologous protein. The safety, pharmacokinetics-dynamics, and immunosuppressive effect of a humanized anti-Tac antibody (HAT) was evaluated in 12 renal transplant recipients. Ten patients received living related transplants (three HLA-identical matches and seven one-haplotype or zero-haplotype matches) and two patients received cadaver organs. The patients were divided into four HAT treatment arms: 0.5 mg/kg/week (n=4), 1 mg/kg/week (n=2), 0.5 mg/kg every other week (n=3), and 1 mg/kg every other week (n=3). The first dose of HAT was given within 12 hr before transplantation, and four additional doses were given after transplantation. Patients were also placed on cyclosporine, steroids, and azathioprine. Only one patient, a recipient of a cadaver kidney in the lowest HAT treatment arm, had a reversible rejection episode. The 10 recipients of living related transplants were compared with 17 historical controls treated with an identical immunosuppressive regimen except for HAT. Whereas none of the HAT-treated living related donor recipients had a rejection episode, 6 of 17 (41%) of the historical controls had a rejection episode in the first year after transplantation. There were no first-dose reactions after HAT therapy or other subsequent side effects. None of the patients experienced opportunistic infections or malignancies. One patient developed low-titer anti-HAT antibodies, although the patient maintained high serum HAT concentrations throughout the study. Immune monitoring showed that there were no changes in the percentage or absolute counts of CD3 cells or T-cell subsets after HAT therapy. However, there was a significant decrease in the number of circulating lymphocytes that expressed free Tac. The overall harmonic mean half-life of HAT was 273 hr. The results of this study indicate that HAT given at 1 mg/kg every other week for a total of five doses may provide therapeutic HAT concentration levels and result in good saturation of Tac receptors for at least 12 weeks after transplantation. In summary, HAT is safe and is well tolerated by patients. Its long half-life and lack of immunization could make it a very useful immunosuppressive drug." @default.
• W2019306593 created "2016-06-24" @default.
• W2019306593 creator A5021253355 @default.
• W2019306593 creator A5026789430 @default.
• W2019306593 creator A5037940977 @default.
• W2019306593 creator A5038428819 @default.
• W2019306593 creator A5039370214 @default.
• W2019306593 creator A5077662405 @default.
• W2019306593 creator A5082894654 @default.
• W2019306593 creator A5088687171 @default.
• W2019306593 date "1997-01-01" @default.
• W2019306593 modified "2023-10-16" @default.
• W2019306593 title "A PHASE I TRIAL OF HUMANIZED ANTI-INTERLEUKIN 2 RECEPTOR ANTIBODY IN RENAL TRANSPLANTATION1" @default.
• W2019306593 cites W13170960 @default.
• W2019306593 cites W1988368135 @default.
• W2019306593 cites W1989671244 @default.
• W2019306593 cites W1993051112 @default.
• W2019306593 cites W1996431651 @default.
• W2019306593 cites W2006336823 @default.
• W2019306593 cites W2011366727 @default.
• W2019306593 cites W2040505385 @default.
• W2019306593 cites W2044843499 @default.
• W2019306593 cites W2046110140 @default.
• W2019306593 cites W2052150715 @default.
• W2019306593 cites W2060516601 @default.
• W2019306593 cites W2065459312 @default.
• W2019306593 cites W2071648784 @default.
• W2019306593 cites W2133811759 @default.
• W2019306593 cites W2165929916 @default.
• W2019306593 cites W2280027108 @default.
• W2019306593 cites W2332754031 @default.
• W2019306593 doi "https://doi.org/10.1097/00007890-199701150-00007" @default.
• W2019306593 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9000657" @default.
• W2019306593 hasPublicationYear "1997" @default.
• W2019306593 type Work @default.
• W2019306593 sameAs 2019306593 @default.
• W2019306593 citedByCount "137" @default.
• W2019306593 countsByYear W20193065932012 @default.
• W2019306593 countsByYear W20193065932013 @default.
• W2019306593 countsByYear W20193065932014 @default.
• W2019306593 countsByYear W20193065932016 @default.
• W2019306593 countsByYear W20193065932019 @default.
• W2019306593 countsByYear W20193065932020 @default.
• W2019306593 crossrefType "journal-article" @default.
• W2019306593 hasAuthorship W2019306593A5021253355 @default.
• W2019306593 hasAuthorship W2019306593A5026789430 @default.
• W2019306593 hasAuthorship W2019306593A5037940977 @default.
• W2019306593 hasAuthorship W2019306593A5038428819 @default.
• W2019306593 hasAuthorship W2019306593A5039370214 @default.
• W2019306593 hasAuthorship W2019306593A5077662405 @default.
• W2019306593 hasAuthorship W2019306593A5082894654 @default.
• W2019306593 hasAuthorship W2019306593A5088687171 @default.
• W2019306593 hasBestOaLocation W20193065931 @default.
• W2019306593 hasConcept C126322002 @default.
• W2019306593 hasConcept C141071460 @default.
• W2019306593 hasConcept C159654299 @default.
• W2019306593 hasConcept C203014093 @default.
• W2019306593 hasConcept C2776760755 @default.
• W2019306593 hasConcept C2779134260 @default.
• W2019306593 hasConcept C2780091579 @default.
• W2019306593 hasConcept C2780303639 @default.
• W2019306593 hasConcept C2781413609 @default.
• W2019306593 hasConcept C2909675724 @default.
• W2019306593 hasConcept C2911091166 @default.
• W2019306593 hasConcept C32611913 @default.
• W2019306593 hasConcept C71924100 @default.
• W2019306593 hasConcept C90924648 @default.
• W2019306593 hasConceptScore W2019306593C126322002 @default.
• W2019306593 hasConceptScore W2019306593C141071460 @default.
• W2019306593 hasConceptScore W2019306593C159654299 @default.
• W2019306593 hasConceptScore W2019306593C203014093 @default.
• W2019306593 hasConceptScore W2019306593C2776760755 @default.
• W2019306593 hasConceptScore W2019306593C2779134260 @default.
• W2019306593 hasConceptScore W2019306593C2780091579 @default.
• W2019306593 hasConceptScore W2019306593C2780303639 @default.
• W2019306593 hasConceptScore W2019306593C2781413609 @default.
• W2019306593 hasConceptScore W2019306593C2909675724 @default.
• W2019306593 hasConceptScore W2019306593C2911091166 @default.
• W2019306593 hasConceptScore W2019306593C32611913 @default.
• W2019306593 hasConceptScore W2019306593C71924100 @default.
• W2019306593 hasConceptScore W2019306593C90924648 @default.
• W2019306593 hasIssue "1" @default.
• W2019306593 hasLocation W20193065931 @default.
• W2019306593 hasLocation W20193065932 @default.
• W2019306593 hasOpenAccess W2019306593 @default.
• W2019306593 hasPrimaryLocation W20193065931 @default.
• W2019306593 hasRelatedWork W1981754714 @default.
• W2019306593 hasRelatedWork W2080339151 @default.
• W2019306593 hasRelatedWork W2370117545 @default.
• W2019306593 hasRelatedWork W2378019284 @default.
• W2019306593 hasRelatedWork W2389946526 @default.
• W2019306593 hasRelatedWork W2584499641 @default.
• W2019306593 hasRelatedWork W3029630957 @default.
• W2019306593 hasRelatedWork W3030709858 @default.
• W2019306593 hasRelatedWork W3083533106 @default.
• W2019306593 hasRelatedWork W939282870 @default.
• W2019306593 hasVolume "63" @default.
• W2019306593 isParatext "false" @default.

• next